All AbMole products are for research use only, cannot be used for human consumption.
ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM.
Adv Sci (Weinh). 2022 Jul;9(21):e2201414.
Bile Acid Conjugation on Solid Nanoparticles Enhances ASBT‐Mediated Endocytosis and Chylomicron Pathway but Weakens the Transcytosis by Inducing Transport
ZCL278 purchased from AbMole
Int J Pharm. 2022 Feb 14;617:121589.
Lipid raft-mediated and upregulated coordination pathways assist transport of glycocholic acid-modified nanoparticle in a human breast cancer cell line of SK-BR-3
ZCL278 purchased from AbMole
Int J Nanomedicine. 2018 Jul 27;13:4391-4404.
Rho GTPases in A549 and Caco-2 cells dominating the endocytic pathways of nanocarbons with different morphologies.
ZCL278 purchased from AbMole
ACS Appl Mater Interfaces. 2017 Feb 22;9(7):5803-5816.
Transmembrane Pathways and Mechanisms of Rod-like Paclitaxel Nanocrystals through MDCK Polarized Monolayer
ZCL278 purchased from AbMole
 |
Source | International Journal of Nanomedicine (2018). Figure 5. ZCL278 (Abmole Bioscience, Houston, TX, USA) |
| Method | RNA interference | |
| Cell Lines | A549 cells | |
| Concentrations | ||
| Incubation Time | 24 h | |
| Results | These findings indicated that Cdc42 played a vital role in the uptake of oxMWCNTs in A549 cells, while Rac1 and RhoA might not be involved in this process. |
. figure 9.jpg) |
Source | ACS Appl Mater Interfaces (2017). Figure 9. ZCL 278 (Abmole BioScience. Houston, TX, USA) |
| Method | Transwells | |
| Cell Lines | MDCK cells | |
| Concentrations | ||
| Incubation Time | ||
| Results | As shown in Figure 9, in the presence of ZCL 278, the transmembrane amount of PTX-NCs was reduced significantly, indicating that Cdc 42 participated in the regulation of the transport of PTX-NCs. |
| Molecular Weight | 584.89 |
| Formula | C21H19BrClN5O4S2 |
| CAS Number | 587841-73-4 |
| Solubility (25°C) | DMSO 70 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Natasha P Murphy, et al. Progress in the therapeutic inhibition of Cdc42 signalling
| Related Ras Products |
|---|
| BBO-8520
BBO-8520 is a first-in-class orally active covalent KRAS G12C inhibitor. BBO-8520 inhibits KRASG12C (ON) by locking the GTP-binding protein in state 1, a conformation incapable of binding effectors, thereby inhibiting the downstream signaling of KRASG12C (ON) that promotes cell proliferation. BBO-8520 also rapidly and completely blocks the RAS-RAF1 interaction, returning KRASG12C to its inactive (OFF) state. |
| RMC-9805
RMC-9805 (KRAS G12D inhibitor 18) is an orally active KRAS G12D inhibitor. RMC-9805 (KRAS G12D inhibitor 18) inhibits RAS signaling and induces apoptosis in KRAS G12D mutant cancer cells. |
| RMC-7977
RMC-7977 is a highly selective, reversible, tri-complex RAS inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants. RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X). |
| KRpep-2d
KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. |
| Rac1 Inhibitor W56
Rac1 Inhibitor W56 is a peptide containing residues 45-60 of Rac1. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
